ArticleMedicine2018
Catheter removal and outcomes of multidrug-resistant central-line-associated bloodstream infection.
Article in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Catheter management across patients with hematologic malignancies and catheter-related blood stream infections: a systematic review.Annals of hematology · 2022Pooled it
- Comparing success rates in central venous catheter salvage for catheter-related bloodstream infections in adult patients on home parenteral nutrition: a systematic review and meta-analysis.The American journal of clinical nutrition · 2021Pooled it
- Risk Prediction of Multidrug-Resistant Infections in Pediatric Burn Patients with Hospital-Acquired Infections: A Retrospective Cohort Study.Plastic and reconstructive surgery · 2026Article
- Practice guideline on the prevention and treatment of central line-associated bloodstream infection: Part 2 - Treatment.Journal of intensive medicine · 2026Article
- Gut colonization with multidrug-resistant organisms in hospitalized patients with gastrointestinal illness: A single-centre, cross-sectional study.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Article
- Catheter-associated bacteremia caused by Asaia lannensis in an immunosuppressed patient: a case report.BMC infectious diseases · 2026Article
- Retention versus replacement or removal of catheters for people with confirmed or suspected intravascular catheter-related infections.The Cochrane database of systematic reviews · 2026Article
- Patterns and Predictors ofJournal of fungi (Basel, Switzerland) · 2025Article
- Effectiveness of Vascular Catheter Removal Versus Retention in Non-ICU Patients with CRBSI or CABSI in Retrospective, Single-Center Study.Microorganisms · 2025Article
- Impact of early infectious diseases consultation on the management of central line-associated bloodstream infection: a propensity score weighting retrospective cohort study.BMC infectious diseases · 2025Article
- Time to positivity as a predictor of catheter-related bacteremia and mortality in adults with Pseudomonas aeruginosa bloodstream infection.Critical care (London, England) · 2025Observational
- Eravacycline Treatment for Carbapenem-ResistantInfection and drug resistance · 2025Article
- Multi-Functional Biomaterial for the Treatment and Prevention of Central Line-Associated Bloodstream Infections.Advanced materials (Deerfield Beach, Fla.) · 2024Article
- Impact of multidrug resistance on outcomes in hematologic cancer patients with bacterial bloodstream infections.Scientific reports · 2024Article
- Improving Activity of New Arylurea Agents against Multidrug-Resistant and Biofilm-ProducingACS medicinal chemistry letters · 2024Article
- Evaluating indwelling devices and other risk factors for mortality in invasive Carbapenem-resistant Enterobacterales infections in Georgia, 2012-2019.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024Article
- Comparison of microbial colonization rates between central venous catheters and peripherally inserted central catheters.Antimicrobial resistance and infection control · 2023Article
- Antimicrobial stewardship in the intensive care unit.Journal of intensive medicine · 2023Review
- Navigating Available Treatment Options for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Review
- Ten Years of KPC-Kp Bloodstream Infections Experience: Impact of Early Appropriate Empirical Therapy on Mortality.Biomedicines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Central-line-associated bloodstream infections (CLABSIs) are responsible for ∼1/3 of all deaths from healthcare-associated infections in the United States. Of these, multidrug-resistant organisms (MDROs) are responsible for 20% to 67%. However, whether catheter removal affects clinical outcomes for MDRO CLABSIs has not been studied. Our objective was to determine the relationship between failure to remove a central venous catheter (CVC) and 30-day all-cause mortality in patients with MDRO CLABSIs. We used a retrospective cohort from Barnes-Jewish Hospital (1/1/2009-10/1/2015) to study patients with a multidrug-resistant Staphylococcus aureus, Enterococcus species, Enterobacteriaceae, Acinetobacter species, or Pseudomonas aeruginosa CLABSI. Risk factors for 30-day mortality, including catheter removal, were assessed for association with 30-day mortality using Cox proportional hazards models. The CLABSIs were assessed prospectively at the time of occurrence by infection prevention specialists. A total of 430 patients met inclusion criteria, 173 (40.2%) with Enterococcus, 116 (27.0%) Enterobacteriaceae, 81 (18.8%) S aureus, 44 (10.2%) polymicrobial, 11 (2.6%) P aeruginosa, and 5 (1.2%) Acinetobacter CLABSIs. Removal of a CVC occurred in 50.2% of patients, of which 4.2% died by 30 days (n = 9). For patients whose CVC remained in place, 45.3% died (n = 97). Failure to remove a CVC was strongly associated with 30-day all-cause mortality with a hazard ratio of 13.5 (6.8-26.7), P < .001. Other risk factors for 30-day mortality included patient comorbidities (cardiovascular disease, congestive heart failure, cirrhosis), and being in an intensive care unit at the time of MDRO isolation. Failure to remove a CVC was strongly associated with 30-day all-cause mortality for patients with MDRO CLABSIs in this single center retrospective cohort. This suggests that patients presenting with MDRO CLABSIs should all undergo CVC removal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.